Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 ...

The cancer center’s first test of the technology matched all of its manually identified clinical trials candidates and found ...

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis. A new combined risk score that incorporates ...

Unstructured clinical data, comprising 80% of health information, presents a significant market opportunity for AI-driven ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported ...

An announcement from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. BriaCell Therapeutics announced positive results from its Phase 2 and ...

Conducting studies in over 50 countries and regions, Caidya specializes in oncology and hematology, rare diseases, pediatrics, cell and gene therapy, cardiovascular, and dermatology. It has emerged as ...

Missing data in clinical trials remains an ongoing concern. With the expansion of data privacy efforts and the consequent inability to contact trial participants for follow-up, the magnitude and ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

This article is part of our series on clinical data considerations. Read How to Prepare for Disclosure. For publicly traded biotech companies, disclosing clinical trial data can be an exciting ...